New biosimilar shows promise for treating wet macular degeneration
Disease control
Completed
This study tested whether a new drug called FYB203 works as well as the standard treatment Eylea for wet age-related macular degeneration, a condition that causes vision loss. 434 adults aged 50 and older took part. The main goal was to see if vision improved after 8 weeks of tre…
Phase: PHASE3 • Sponsor: Bioeq GmbH • Aim: Disease control
Last updated May 04, 2026 16:22 UTC